Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  GlaxoSmithKline    GS7   GB0009252882

GLAXOSMITHKLINE (GS7)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 06/21 08:14:24 pm
17.549 EUR   -0.95%
02:59pGILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to..
RE
07:40aGLAXOSMITHKLINE : Savvy senior
AQ
06/18KRAFT HEINZ : WHAT A HORLICKS Malted milk drink with 145-year histor..
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

GlaxoSmithKline: Positive Results for ViiV Healthcare's HIV Studies

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/14/2018 | 08:45am CEST

By Maryam Cockar

GlaxoSmithKline said Thursday that its subsidiary, ViiV Healthcare Ltd, has reported positive phase 3 studies for the dolutegravir and lamivudine drugs, demonstrating the ability to control HIV with a two-drug regimen.

GSK said that the GEMINI 1 and 2 studies demonstrated a similar efficacy of a two-drug regimen compared with the standard three-drug regimen in patients that have never undergone treatment for a specific illness.

"The GEMINI studies demonstrate the potency, safety and tolerability of the dolutegravir plus lamivudine combination. They affirm our two-drug regimen strategy, and reinforce our belief that many patients can control their disease with two drugs instead of three or more. Importantly, the studies show that this two-drug regimen could be an option for treatment naive patients and can support a broad range of patients living with HIV around the world," said John Pottage, chief scientific and medical officer of ViiV Healthcare.

GSK said the GEMINI studies are part of ViiV Healthcare's clinical-trial program "for two-drug regimens that seeks to address long-term toxicity concerns of people living with HIV by reducing the number of medicines used in their treatment".

Specialist HIV company ViiV Healthcare is majority owned by GSK, with Pfizer and Shionogi & Co. (4507.TO).

Write to Maryam Cockar at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 0.00% 1550 Delayed Quote.17.20%
PFIZER 0.66% 36.46 Delayed Quote.-0.17%
SHIONOGI & CO LTD 1.90% 5781 End-of-day quote.-6.58%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
02:59pGILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
07:40aGLAXOSMITHKLINE : Savvy senior
AQ
06/18GLAXOSMITHKLINE : Health and Human Services Department (HHS); Food and Drug Admi..
AQ
06/18KRAFT HEINZ : WHAT A HORLICKS Malted milk drink with 145-year history now a £3bn..
AQ
06/16International fund managers turn to financials, tech as trade worries rise
RE
06/16GLAXOSMITHKLINE : aids Sri Pada pilgrims for ninth consecutive year
AQ
06/16GLAXOSMITHKLINE : Panadol ranked as Sri Lanka's 2nd 'Most Loved Brand'
AQ
06/15Glaxo Pops But Analysts Say It`s Unlikely To Swipe Gilead Share In HIV
AQ
06/15Mylan expecting another delay for generic Advair
AQ
06/15ViiV's two-drug HIV regimen meets in Phase III for HIV
AQ
More news
Financials ( GBP)
Sales 2018 29 808 M
EBIT 2018 7 924 M
Net income 2018 3 804 M
Debt 2018 19 412 M
Yield 2018 5,16%
P/E ratio 2018 20,68
P/E ratio 2019 16,75
EV / Sales 2018 3,23x
EV / Sales 2019 3,10x
Capitalization 77 011 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GS7 | GB0009252882 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 27
Average target price 15,6  GBP
Spread / Average Target 0,63%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE18.75%101 387
JOHNSON & JOHNSON-13.17%325 398
PFIZER-0.17%211 520
NOVARTIS-8.25%188 977
ROCHE HOLDING LTD.-14.38%182 331
MERCK AND COMPANY8.46%164 082